Mr. Gilles Gagnon reports

CEAPRO INC. ANNOUNCES POSITIVE DATA FROM BIOAVAILABILITY STUDIES EVALUATING COQ10 FORMULATIONS IMPREGNATED WITH PGX-PROCESSED CARRIERS

Ceapro Inc. has released positive results from its collaborative project led by Dr. Donna Vine, professor at the department of agriculture, food and nutritional science of the University of Alberta.

In this study, titled "Pre-clinical Testing of Intestinal Bioavailability of CoQ10-Formulations," four PGX-processed (pressurized gas expanded) highly purified carriers, outlined in the attached table, were loaded (impregnated) with coenzyme Q10 (CoQ10) and compared against two positive controls: a food-grade lipid-based formulation (CoQ10 in triolein or oil), and one of the best commercially available dry powder formulations, cyclodextrin loaded with 22.1 per cent CoQ10.

In the summary report of the project, Dr. Vine concludes, "This in vivo pilot study shows that following eight hours, the 5.8 per cent iYBG and 20 per cent iAL CoQ10 formulations have increased bioavailability of CoQ10 up to two to threefold higher compared to food-grade CoQ10 in triolein and 22.1 per cent commercial complex (cyclodextrin) formulations." Furthermore, an additional four hours of tissue collection (up to 12 hours) demonstrated an additional 30-per-cent increase in CoQ10 absorption in the 22.5 per cent i(AL+YBG) formulation, highlighting the prolonged or delayed metabolism absorption of CoQ10 which may also infer long-acting metabolic benefits of CoQ10.

"With our recent announcement of the successful development and publication of new chemical conjugates like PGX alginate loaded with CoQ10, we are very pleased to have demonstrated in vivo a superior bioavailabilty for these new chemical complexes with CoQ10 even when it is mixed in water formulation where bioavailabilty has always been a challenge for most commercial CoQ10 supplements. Knowing that Ceapro's PGX-processed carriers can deliver CoQ10 into the tissues, we will advance to the next stage, which includes looking for efficacy of these new chemical entities along with a partner involved in the marketing and sales of various forms of delivery systems that can be included in food, drinks, cream formulations, medical supplies like thin films, skin patches, and up to nutraceuticals and pharmaceuticals," said Gilles Gagnon, MSc, MBA, president and chief executive officer. "Additionally, we are excited about some data strongly suggesting that we have a slow-release formulation when combining i(AL+YBG) with CoQ10 (eight to 12 hours), which would be a first-in-class product. In summary, these results with alginate and yeast beta glucan as carriers for CoQ10 and possibly other bioactives support our investment decision for the next scale-up level of the PGX technology and the expansion of our pipeline targeting a large market potential."

About pressurized gas expanded liquid technology (PGX)

Ceapro's patented pressurized gas expanded (PGX) technology is a unique and disruptive technology with several key advantages over conventional drying and purification technologies that can be used to process biopolymers into high-value, fine-structured, open-porous polymer structures and novel biocomposites. PGX is ideally suited for processing challenging high-molecular-weight, water-soluble biopolymers. It has the ability to make ultralight, highly porous polymer structures on a continuous basis, which is not possible using today's conventional technologies. PGX was invented by Dr. Feral Temelli from the department of agricultural, food and nutritional science of the University of Alberta (U of A) along with Dr. Bernhard Seifried, now senior director of engineering research and technology at Ceapro. The licence from U of A provides Ceapro with exclusive worldwide rights in all industrial applications.

About Ceapro Inc.

Ceapro is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical and therapeutics products for humans and animals. The company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.

We seek Safe Harbor.